AnnSofie Sternas - Karolinska Development Insider

Karolinska Development AB -- Sweden Stock  

SEK 5.44  0.1  1.81%

Vice President IPR

Ms. AnnSofie Sternas was Vice President IPR at Karolinska Development AB since June 2012. She is European Patent Attorney and holds MS in Chemical Engineering. AnnSofie Sternas has almost 20 years of IP experience from large pharmaceutical companies and has held senior IPR positions within Astra and AstraZeneca. During many years AnnSofie was heavily involved in IP litigation of several blockbuster drugs. AnnSofie is specialized in IPstrategic matters with a heavy focus on the US legislation particularly IP in the interface between patent law and regulatory law. She is also part of a number of management teams within the Karolinska Development portfolio companies.
Age: 53  President Since 2012      
46 8 52 48 60 70

Management Efficiency

The company has return on total asset (ROA) of (3.53) % which means that it has lost $3.53 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 86.56 % meaning that it generated $86.56 on every $100 dollars invested by stockholders.
The company has accumulated 368.41 M in total debt with debt to equity ratio (D/E) of 156.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 15.89 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 5 records


Bjorn FrendeusBioInvent International AB
PerAnders JohanssonBioInvent International AB
Trevor JuniperBioInvent International AB
Martin WilesBioInvent International AB
Kristoffer HanssonBioInvent International AB

Entity Summary

Karolinska Development AB is a VC firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Solna, and employs 13 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karolinska Development AB to your portfolio

Top Management

Karolinska Development AB Leadership Team
Hans Wigzell, Chairman, Ph.D
Elisabet Gimbringer, Executive
Carl Sundberg, Director
Magnus Persson, Director, Ph.D
Jim Heusden, CEO, Ph.D
Maria Ferm, Executive
HansOlov Olsson, Director, Ph.D
Theresa Tse, Director
Viktor Drvota, Executive, Ph.D
Eva Montgomerie, Executive
Michael Owens, Executive
Yan Cheng, President
Ulf Richenberg, Executive
Niclas Adler, Director
Tse Ping, Director, Ph.D
Christian Tange, CFO, MBA
Daniel Bolanowski, Executive
Terje Kalland, Executive, Ph.D
Vladimir Artamonov, Director, MBA
Felicia Rittemar, Executive
AnnSofie Sternas, President
Anders Harfstrand, Director, Ph.D
Bo Hansen, Chairman, Ph.D
Viktor MD, Executive
Khalid Islam, Director, Ph.D
Gunilla Ekstrom, President, Ph.D
Henrijette Richter, Director

Stock Performance

Karolinska Development Performance Indicators